Telomir Pharmaceuticals, Inc. · NASDAQ:TELO
Telomir Pharmaceuticals — Investor Presentation (April 2026)
43 slides from Telomir Pharmaceuticals's investor presentation, April 2026
Slide 1: Targeting Fundamental Drivers of Cancer Through Metal-Dependent Epigenetic Regulation
Targeting Fundamental Drivers of Cancer Through Metal-Dependent Epigenetic Regulation April 2026 NASDAQ: TELO
Slide 2: Corporate Overview
Corporate Overview Telomir Pharmaceuticals (Nasdaq: TELO) is a biotech company developing Telomir-1, a first-in-class oral small molecule targeting iron-driven epigenetic mechanisms in T E L O M I R P H A R M A . C O M cancer, with an initial focus on triple-negative breast cancer (TNBC). The Compan
Slide 3: First-in-Class Oral Therapy Targeting Iron-Driven Epigenetic Mechanisms in Cancer
First-in-Class Oral Therapy Targeting Iron-Driven Epigenetic Mechanisms in Cancer Demonstrated Preclinical Activity Across: Telomir-1 Modulates Fundamental Biological Oncology: Processes By: • Triple-negative breast cancer (TNBC) T E L O M I R P H A R M A . C O M • Regulating intracellular iron and
Slide 4: Our Pipeline
Our Pipeline Indications Pre-Clinical Phase-I/II Phase-II/III Triple-Negative Breast Cancer T E L O M I R P H A R M A . C O M (TNBC) Telomir-1 AMD Wilson’s disease Investor Presentation | NASDAQ: TELO 3
Slide 5: Telomir Management
Telomir Management Erez Aminov | Chairman & CEO Itzchak Angel, PhD | Chief Scientific Advisor ▪ Biotechnology executive with a track record of advancing drug ▪ Over 40 years of experience in guiding medical, pharmaceutical, candidates from preclinical development through IND submission and drug, and
Slide 6: Telomir Advisors
Telomir Advisors Francis E. O’Donnell, Jr., M.D. | Special Advisor Michael Roizen, M.D. | Special Advisor ▪ Dr. O’Donnell leads clinical strategy and evaluates potential ▪ Dr. Michael Roizen, an advisor to the Company since 2023, is Chief products for unmet medical needs. Wellness Officer Emeritus a
Slide 7: Impact of Iron Overload
Cellular Impact of Iron Overload ▪ Oxidative stress ▪ Mitochondrial dysfunction ▪ DNA dysfunction Iron Overload ▪ Epigenetics ▪ Ferroptosis ▪ Cellular senescence T E L O M I R P H A R M A . C O M Functional ▪ Cancer ▪ Accelerated aging Pathology ▪ Senescence ▪ Cancer ▪ Telomer shortening ▪ Progeria
Slide 8: Telomir-1 Can Effectively Bind and Modulate Several Ions
Telomir-1 Can Effectively Bind and Modulate Several Ions: High Affinity for Iron and Copper and Lower Affinity for Zinc T E L O M I R P H A R M A . C O M White: Hydrogen Blue: Nitrogen Gray: Carbon Orange: Metal Investor Presentation | NASDAQ: TELO 7
Slide 9: Mechanism of Action
Mechanism of Action Telomir-Zn enters the cell, captures excess iron or copper, and swaps them for protective zinc — removing toxic metals and restoring healthy cellular balance. T E L O M I R P H A R M A . C O M + In the Cell Outside the Cell Investor Presentation | NASDAQ: TELO 8
Slide 10: Telomir-Zn Can Replace Iron by Copper but Not by Zinc
Telomir-Zn Can Replace Iron by Copper but Not by Zinc Zinc does not compete Copper competes with with iron on the binding to iron on the binding to Telomir-Zn Telomir-Zn restoring the levels of free Fe2+ Telomir-Zn reduces Telomir-Zn reduces the levels of free Fe2+ the levels of free Fe2+ Copper Rep
Slide 11: Mechanism of Action
Mechanism of Action Direct measurements in HaCat cells of the effects of Telomir-1 on intracellular iron, as stained with FerroOrange at 24 hours: T E L O M I R P H A R M A . C O M High Intracellular Iron (Yellow Color) Reduced Intracellular Iron (Yellow Color) Relative Relative Intensity Intensity
Slide 12: Telomir-1 Achieves Greater Intracellular Iron Reduction Than DFO at 6 Hours
Telomir-1 Achieves Greater Intracellular Iron Reduction Than DFO at the 6- Hour Mark, Even Though DFO is the Stronger Chelator in Vitro T E L O M I R P H A R M A . C O M Incubation time :6 hours Investor Presentation | NASDAQ: TELO 11
Slide 13: Telomir-Zn Induces an Exchange Between Intracellular Iron and Zinc
Telomir-Zn Induces an Exchange Between Intracellular Iron and Zinc Enhanced Intracellular Zinc Levels Reduced Intracellular Iron Levels Investor Presentation | NASDAQ: TELO 12
Slide 14: Mechanism of Action
Mechanism of Action Telomir-Zn enters the cell, captures excess iron or copper, and swaps them for protective zinc — removing toxic metals and restoring healthy cellular balance. T E L O M I R P H A R M A . C O M In the Cell + Outside the Cell Investor Presentation | NASDAQ: TELO 13
Slide 15: Cancer Research
Cancer Research • Anti-cancer activity T E L O M I R P H A R M A . C O M • Epigenetics • Mechanisms of action Investor Presentation | NASDAQ: TELO 14
Slide 16: Investor Presentation | NASDAQ: TELO 15
Investor Presentation | NASDAQ: TELO 15
Slide 17: Anti-Cancer Activity in TNBC Cells - MDA 468 Cells
Anti-Cancer Activity in TNBC Cells - MDA 468 Cells Results: • Telomir-1 reduced cell viability in MDA 468 TNBC cells Significance: • Suggests Telomir-1 may hold potential as a novel therapeutic candidate for TMBC tumors IC50= 1.4 µM Investor Presentation | NASDAQ: TELO 16
Slide 18: Anti-Cancer Activity in TNBC Cells – MDA-MB 468 Cells Effect on Iron
Anti-Cancer Activity in TNBC Cells – MDA-MB 468 Cells Effect on Iron Results: • Telomir-Zn reduced cell viability in MDA –MB 468 TNBC cells • Presence of Iron (10 µM) protects the cells from this effect IC50= 30.9 µM Significance: • Suggests Telomir-Zn may hold potential as a novel therapeutic candi
Slide 19: Telomir-Zn Has Significant, but Variable Anti-Cancer Activity in Different Cancer Cell Types
Telomir-Zn Has Significant, but Variable Anti-Cancer Activity in Different Cancer Cell Types Cell line used Cancer Type Telomir-Zn IC50 (µM) Telomir-Zn kills different cancer cell types with HCC 1806 TNBC 0.87 variable potency MDA-MB-468 1.5 Results: HCC 70 3.6 • Telomir-Zn reduced cell viability mo
Slide 20: Potency of Telomir-Zn Correlates with Iron Addiction Properties
Potency of Telomir-Zn in Different Cells Correlates with “Iron Addiction” Properties of the Cells Cell line used Cancer Type Telomir-Zn IC50 (µM) HCC 1806 TNBC 0.87 MDA-MB-468 1.5 HCC 70 3.6 HL 60 Leukemia 1.6 PC3 Prostate (Androgen- 14.3 independent) LNCap Prostate (Androgen- 21.3 dependent) PANC-1
Slide 21: Significant Anti-Cancer Activity in BT 549 TNBC Model
Significant Anti-Cancer Activity in BT 549 TNBC Model Key Study Highlights: Model Used: • Human triple negative breast cancer BT549 cells in zebrafish xenograft model • Telomir-Zn was administered orally daily for 3 days to zebra fish embryos implanted with BT549 cells Results: • Telomir-Zn showed t
Slide 22: Significant Anti-Cancer Activity in BT 549 TNBC Model
Significant Anti-Cancer Activity in BT 549 TNBC Model Key Study Highlights: Model Used: • Human triple negative breast cancer BT549 cells in zebrafish xenograft model • Telomir-Zn was administered orally daily for 3 days to zebra fish embryos implanted with BT549 cells Results: • Telomir-Zn showed t
Slide 23: Significant Anti-Cancer Activity in Chemotherapy Resistant HCC1806 TNBC Model
Significant Anti-Cancer Activity in Chemotherapy Resistant HCC1806 TNBC Model Key Study Highlights: Model Used: • Human triple negative chemotherapy resistant breast cancer HCC1806 cells, in zebrafish xenograft model • Telomir-1 was administered orally daily for 3 days to zebra fish embryos implante
Slide 24: Significant Anti-Cancer Activity in Prostate Cancer Xenograft Mice Model
Significant Anti-Cancer Activity in Prostate Cancer Xenograft Mice Model Key Study Highlights: Model Used: • Human prostate cancer PC3 cells in mice xenograft model • Telomir-Zn was administered orally daily for 21 days to mice implanted with PC3 cells Results: • Telomir-Zn showed tumor volume suppr
Slide 25: Telomir-1 Reduces DNA Methylation of Key Proteins
Telomir-1 Reduces DNA Methylation of Key Proteins PC3 Prostate Cancer Model Investor Presentation | NASDAQ: TELO 24
Slide 26: Telomir-1 Reduces DNA Methylation of Key Proteins
Telomir-1 Reduces DNA Methylation of Key Proteins PC3 Prostate Cancer Model Investor Presentation | NASDAQ: TELO 25
Slide 27: Restoring Tumor-Suppressor Genes Through Epigenetic Regulation
Restoring Tumor-Suppressor Genes Through Epigenetic Regulation Key Highlights: • Prostate cancer progression is driven by abnormal DNA methylation that silences key tumor-suppressor genes (e.g., GSTP1, CDKN2A, RASSF1A, MASPIN). • Study used a PC3 human prostate cancer xenograft model, measuring DNA
Slide 28: Telomir-Zn Potently Inhibits Histone Demethylases KDM2 and KDM6
Telomir-Zn Potently Inhibits Histone Demethylases (KDMs) - KDM2 and KDM6 Key epigenetic enzymes driving cancer growth, inflammation, and aging. Key Study Highlights: • FBXL10 (KDM2B) / FBXL11 (KDM2A): Cancer-driving enzymes that support tumor growth, stem-like behavior, and immune evasion • UTX (KDM
Slide 29: Telomir-Zn Potently Inhibits Histone Demethylases (KDM5s, JARID1)
Telomir-Zn Potently Inhibits Histon Demethylases 5 (KDM5s, JARID1) Key Study Highlights: • JARID1A (KDM5A): Epigenetic eraser that shuts down tumor-suppressor genes by removing activation marks. • JARID1B (KDM5B): Drives cancer stem-cell survival by stripping activation marks that limit tumor growth
Slide 30: Exploring the Role of KDMs in Controlling Gene Activity
Exploring the Role of KDMs in Controlling Gene Activity Key Highlights: • KDMs regulate gene activity by removing methyl groups from histones. • Dysregulated KDMs alter oncogene and tumor-suppressor control. • These enzymes require iron, linking them to cellular redox states. Model: • Telomir-Zn tes
Slide 31: Telomir-Zn Only Mildly Inhibits Tankyrases (PARP5)
Telomir-Zn Only Mildly Inhibits Tankyrases (PARP5) Tankyrases regulate the Wnt/β-catenin growth pathway that many cancers rely on for uncontrolled proliferation. Key Study Highlights: • Telomir-Zn shows low-level inhibition of Tankyrases (PARP5A/B), key regulators of the Wnt/β-catenin growth T E L O
Slide 32: Multifactorial Interaction of Telomir-Zn on Key Processes
Multifactorial Interaction of Telomir-Zn on Key Processes • Many tumors exhibit an iron-addiction phenotype characterized by increased transferrin receptor expression, ferritin buffering, and expansion of the labile iron pool. • Iron supports the activity of Fe-dependent lysine demethylases (KDMs) t
Slide 33: Comparison of Deferoxamine and Telomir-Zn
Property Deferoxamine (DFO) Telomir-Zn Primary metal Fe³⁺ >Fe2⁺ >>>Cu2⁺ Cu2⁺ >Fe2⁺ >>>Fe³⁺ interaction Comparison of Cell permeability Low (hydrophilic) Higher (lipophilic scaffold) Deferoxamine and Pharmacokinetics Poor oral absorption, short half-life Designed for better cellular and oral penetrat
Slide 34: Integrating the Beneficial Effect of Zinc in Cancer
Integrating the Beneficial Effect of Zinc in Cancer • Many cancers exhibit an iron-addiction phenotype, and expansion of the labile iron pool, promoting ROS generation and activity of Fe²⁺-dependent lysine demethylases (KDMs). • Telomir-Zn restores metal homeostasis by introducing redox-inert zinc,
Slide 35: Pre-Clinical Research Summary
Pre-Clinical Research Summary Domain Main characteristics details Pharmacology Selective metal ion chelator Fe>Cu>>Zn • Telomir-1 is rapidly absorbed in rat and dog with rapid elimination half-life T E L O M I R P H A R M A . C O M ADME Absorption • Was stable in mouse, rat, dog, monkey, and human p
Slide 36: Telomir-1 Clinical Study Overview
Telomir-1 Clinical Study Overview • First-in-Human (FIH), Phase I/II study T E L O M I R P H A R M A . C O M • Population: Advanced / Metastatic TNBC • Design: Multicenter, open-label • Investigational product: Telomir-Zn (oral) • Protocol: TELO-001 Investor Presentation | NASDAQ: TELO 35
Slide 37: Scientific & Clinical Rationale
Scientific & Clinical Rationale • TNBC lacks durable targeted therapies T E L O M I R P H A R M A . C O M • Telomir-Zn: Oral metal-regulating epigenetic modulator • Targets iron-dependent chromatin enzymes • Restores tumor suppressor transcriptional control • Induces replication & oxidative stress i
Slide 38: Study Design – Phase I/II study
Study Design – Phase I/II study • Phase I: Modified 3+3 dose escalation T E L O M I R P H A R M A . C O M • Dose levels: 50 → 400 mg QD • Intermittent schedule (14 days on / 14 days off), 2 to 4 cycles • DLT window: 28 days + cumulative review • RP2D selection based on safety + PK/PD Investor Presen
Slide 39: Phase II Expansion Strategy
Phase II Expansion Strategy • Simon two-stage minimax design T E L O M I R P H A R M A . C O M • Stage 1: n = 15 participants • Stage 2: n = 25 (if threshold met) • Primary endpoint: ORR (RECIST v1.1) • Early stopping rules applied Investor Presentation | NASDAQ: TELO 38
Slide 40: Key Endpoints
Key Endpoints • Primary (Phase I): Safety, tolerability, MTD, RP2D T E L O M I R P H A R M A . C O M • Primary (Phase II): Objective Response Rate (ORR) • Secondary: PK (Cmax, AUC, T½, AR) • Secondary: PD epigenetic biomarkers • Exploratory: Telomere & histone markers Investor Presentation | NASDAQ:
Slide 41: Strategic Significance
Strategic Significance • Novel epigenetic mechanism in TNBC T E L O M I R P H A R M A . C O M • Targets iron-dependent tumor vulnerabilities • Oral administration → improved compliance • Integrated PK / PD biomarker framework • Platform potential across indications Investor Presentation | NASDAQ: TE
Slide 42: Growth Strategy
Growth Strategy Continue pre-clinical development of Telomir-1 across a range of diseases and progress into T E L O M I R P H A R M A . C O M clinical development Advance Telomir-1 through clinical development and FDA approval Identify additional product candidates and expand current candidates into
Slide 43: Thank you.
Thank you. 100 SE 2nd Street Suite 2000 #1009 Miami, FL 33131 TelomirPharma.com
Telomir Pharmaceuticals — Investor Presentation (April 2026) on 6ix